PFM
RNAC icon

Privium Fund Management’s Cartesian Therapeutics RNAC Stock Holding History

Privium Fund Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Sell
151,675
-27,439
-15% -$203K 0.29% 38
2026
Q1 		$1.1M Buy
179,114
+6,614
+4% +$47.1K 0.23% 42
2025
Q4 		$1.24M Buy
+172,500
New +$1.39M 0.23% 40

Other funds holding RNAC

Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Privium Fund Management's RNAC Position: Q2 2026 in Review

Privium Fund Management reduced its Cartesian Therapeutics (RNAC) stake by 15% in Q2 2026, selling an estimated $203K and leaving 151,675 shares worth $1.58M. The position accounts for 0.29% of the portfolio, ranked #38.

Privium Fund Management first reported a position in RNAC in Q4 2025 and has held it in 3 quarters since. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.

  • Privium Fund Management held 151,675 shares of Cartesian Therapeutics worth $1.58M as of Q2 2026.
  • Privium Fund Management sold 27,439 Cartesian Therapeutics shares in Q2 2026, an estimated $203K.
  • Cartesian Therapeutics made up 0.29% of Privium Fund Management's portfolio in Q2 2026, its #38 holding.
  • Privium Fund Management first reported a position in Cartesian Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.